JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM) fundamentals
JB Chemicals & Pharmaceuticals Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as JBCHEPHARM (ISIN INE572A01036). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What JB Chemicals & Pharmaceuticals Limited does
J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company specializes in gastroenterology, hypertension and dermatology. It is also focused on other therapeutic categories like nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT). The Company is engaged in the business of manufacturing and marketing of a diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. It specializes in manufacturing medicated and herbal lozenges. It produces hard-candy lozenges, soft-center lozenges and powder-filled lozenges for varied medical needs. Its API products include Diclofenac Sodium, Diclofenac Diethylamine, Diclofenac Acid, Nifedipine, and others. It maintains a direct presence in Russia and South Africa, while leveraging distributor partnerships across the United States, Asia, Africa, and Latin America.
Valuation and market data
| Last close | ₹0.00 |
|---|---|
| Market capitalisation | ₹0 crore |
| Enterprise value | ₹0 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.00 |
| Price to sales (TTM) | 0.00 |
| Book value per share | ₹0.00 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Apr 29 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹4,208 crore | ₹952 crore | ₹709 crore | 45.16 |
| Mar 2025 | ₹3,956 crore | ₹887 crore | ₹660 crore | 42.45 |
| Mar 2024 | ₹3,521 crore | ₹752 crore | ₹553 crore | 35.66 |
| Mar 2023 | ₹3,159 crore | ₹555 crore | ₹410 crore | 53.00 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Mar 2026:
| Promoters | 48.8% |
|---|---|
| Foreign institutions (FII) | 16.3% |
| Mutual funds | 19.0% |
| Other domestic institutions | 2.4% |
| Retail and others | 13.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.